Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 7/20 | 0.54 |
| ▸ | GABRD | O14764 | 7/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 7/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.54 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.54 |
| ▸ | GABRE | P78334 | 7/20 | 0.54 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.54 |
| ▸ | GABRG1 | Q8N1C3 | 7/20 | 0.54 |
| ▸ | GABRG3 | Q99928 | 7/20 | 0.54 |
| ▸ | GABRQ | Q9UN88 | 7/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1559868 | 0.83 | GABRP (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1427646 | 0.82 | CHEK1 (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2215855 | 0.77 | CHEK1 (0.33) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL473757 | 0.76 | GABRA1 (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL473696 | 0.76 | CHEK1 (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1561221 | 0.76 | GABRP (0.66) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1560453 | 0.75 | DYRK1A (0.46) | CHEK1 | |
| SCHEMBL1561301 | 0.74 | CHEK1 (0.68) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL20685590 | 0.74 | ACHE (0.54) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1561167 | 0.73 | WNT1 (0.41) | CHEK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| EP-2411389-A2 | 9H-PYRROLO[2,3-B: 5,4-C']DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| EP-2303882-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010109084-A2 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109084-A2 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2009150381-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009150381-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | GABRP 2845/4885GABRD 3188/4885GABRA1 2143/4885 |
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NPR3, CCNH, CBR3 | GABRP 2385/4885GABRD 2005/4885GABRA1 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.